Basit öğe kaydını göster

dc.contributor.authorOTUK, G
dc.contributor.authorATES, S
dc.contributor.authorKUSCU, I
dc.contributor.authorTUNCEL, T
dc.date.accessioned2021-03-04T09:48:43Z
dc.date.available2021-03-04T09:48:43Z
dc.date.issued1994
dc.identifier.citationTUNCEL T., OTUK G., KUSCU I., ATES S., "NASAL ABSORPTION OF ROXITHROMYCIN FROM GEL PREPARATIONS IN RABBITS", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, cilt.40, sa.1, ss.24-26, 1994
dc.identifier.issn0939-6411
dc.identifier.othervv_1032021
dc.identifier.otherav_6a0e2eab-1355-4265-b1a7-1745c4114572
dc.identifier.urihttp://hdl.handle.net/20.500.12627/73433
dc.description.abstractGel preparations of roxithromycin prepared with polymers such as sodium carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC), hydroxypropyl-methyl cellulose (HPMC) and carbopol-polyethylene glycol (PEG), were administered into the nasal cavity of rabbits. Besides, a nasal aqueous suspension of roxithromycin was also applied. The results were compared with oral and intravenous administrations. The bioavailability of the roxithromycin gel formulation prepared with CMC was almost identical to that of the i.v. route and it decreased in the order of HEC, HPMC and carbopol-PEG. Although the dose of roxithromycin in each nasal formulation was 40% of the commercial tablet form, nasal administration was superior to that of the oral route for all three gel formulations except the one with carbopol-PEG. This study carried out on rabbits shows that with a nasal application of roxithromycin-CMC gel preparation, a 95% bioavailability can be attained and the single dose of the commercial tablet can be reduced by 60%.
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectTemel Eczacılık Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleNASAL ABSORPTION OF ROXITHROMYCIN FROM GEL PREPARATIONS IN RABBITS
dc.typeMakale
dc.relation.journalEUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
dc.contributor.department, ,
dc.identifier.volume40
dc.identifier.issue1
dc.identifier.startpage24
dc.identifier.endpage26
dc.contributor.firstauthorID115046


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster